Literature DB >> 10817701

Comparison of fluconazole and itraconazole in a rabbit model of coccidioidal meningitis.

K N Sorensen1, R A Sobel, K V Clemons, D Pappagianis, D A Stevens, P L Williams.   

Abstract

Coccidioidal meningitis is a devastating disease that requires long-term therapy with little hope of cure. A rabbit model of coccidioidal meningitis was used to compare the therapeutic efficacies of fluconazole (FCZ) and itraconazole (ITZ). Hydrocortisone-treated male New Zealand white rabbits were infected intracisternally with 5.0x10(4) to 5.4x10(4) arthroconidia of Coccidioides immitis. Oral treatment with polyethylene glycol 200 (PEG) (n = 9), FCZ (n = 8; 80 mg/kg of body weight/day), or ITZ (n = 8; 80 mg/kg/day) began 5 days after infection and continued for 28 consecutive days. Both FCZ and ITZ reduced the number of CFU of C. immitis organisms in the spinal cord and brain compared with the number in PEG-treated animals (P< or =0.003), but the results for FCZ and ITZ were not different from each other. Histopathologic severity (semiquantitative scoring system by an observer blinded to treatment) was equally reduced in both FCZ and ITZ treatment groups compared with that in controls (P< or =0.0004). Both treatments resulted in lower cerebrospinal fluid (CSF) protein concentrations and leukocyte counts and faster clearing of C. immitis from CSF compared with the results for PEG-treated controls. Neither drug affected CSF glucose levels. Both compounds were effective at reducing neurological and systemic signs and extending survival (P< or =0.014). FCZ was more effective at reducing head and body shakes, posture changes, and incontinence; ITZ was more effective at reducing continuous fever. Mean levels of FCZ and ITZ in the serum and CSF were determined by bioassay; at 17 to 26 h postdosing, levels were 28.1 to 40.0 and 22.4 to 29.9 microg/ml, respectively, for FCZ and 0.77 to 2.51 and 0 microg/ml, respectively, for ITZ. The sera of most animals developed antibody to C. immitis, but azole treatment attenuated antibody development in CSF and its titer. In conclusion, both FCZ and ITZ were efficacious, but neither was curative in a rabbit model of coccidioidal meningitis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10817701      PMCID: PMC89905          DOI: 10.1128/AAC.44.6.1512-1517.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  26 in total

1.  Fluconazole penetration into cerebrospinal fluid: implications for treating fungal infections of the central nervous system.

Authors:  C A Arndt; T J Walsh; C L McCully; F M Balis; P A Pizzo; D G Poplack
Journal:  J Infect Dis       Date:  1988-01       Impact factor: 5.226

2.  Fluconazole distribution to the brain: a crossover study in freely-moving rats using in vivo microdialysis.

Authors:  H Yang; Q Wang; W F Elmquist
Journal:  Pharm Res       Date:  1996-10       Impact factor: 4.200

3.  Itraconazole: pharmacologic studies in animals and humans.

Authors:  H Van Cauteren; J Heykants; R De Coster; G Cauwenbergh
Journal:  Rev Infect Dis       Date:  1987 Jan-Feb

4.  Comparison of itraconazole and fluconazole in treatment of cryptococcal meningitis and candida pyelonephritis in rabbits.

Authors:  J R Perfect; D V Savani; D T Durack
Journal:  Antimicrob Agents Chemother       Date:  1986-04       Impact factor: 5.191

5.  Itraconazole therapy for chronic coccidioidal meningitis.

Authors:  R M Tucker; D W Denning; B Dupont; D A Stevens
Journal:  Ann Intern Med       Date:  1990-01-15       Impact factor: 25.391

Review 6.  Pharmacokinetics and tissue penetration of fluconazole in humans.

Authors:  K W Brammer; P R Farrow; J K Faulkner
Journal:  Rev Infect Dis       Date:  1990 Mar-Apr

7.  Survival improvement in coccidioidal meningitis by high-dose intrathecal amphotericin B.

Authors:  E L Labadie; R H Hamilton
Journal:  Arch Intern Med       Date:  1986-10

8.  High-dose ketoconazole for treatment of fungal infections of the central nervous system.

Authors:  P C Craven; J R Graybill; J H Jorgensen; W E Dismukes; B E Levine
Journal:  Ann Intern Med       Date:  1983-02       Impact factor: 25.391

9.  Treatment of mycoses with itraconazole.

Authors:  R M Tucker; P L Williams; E G Arathoon; D A Stevens
Journal:  Ann N Y Acad Sci       Date:  1988       Impact factor: 5.691

10.  Pharmacokinetics of fluconazole in cerebrospinal fluid and serum in human coccidioidal meningitis.

Authors:  R M Tucker; P L Williams; E G Arathoon; B E Levine; A I Hartstein; L H Hanson; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1988-03       Impact factor: 5.191

View more
  10 in total

1.  Reflections on the approach to treatment of a mycologic disaster.

Authors:  David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2013-02-05       Impact factor: 5.191

2.  What can we learn and what do we need to know amidst the iatrogenic outbreak of Exserohilum rostratum meningitis?

Authors:  Dimitrios P Kontoyiannis; David S Perlin; Emmanuel Roilides; Thomas J Walsh
Journal:  Clin Infect Dis       Date:  2013-05-06       Impact factor: 9.079

3.  Comparison of itraconazole and fluconazole treatments in a murine model of coccidioidal meningitis.

Authors:  Perparim Kamberi; Raymond A Sobel; Karl V Clemons; Andreas Waldvogel; Joan M Striebel; Paul L Williams; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2006-12-18       Impact factor: 5.191

4.  Successful use of combination antifungal therapy in the treatment of coccidioides meningitis.

Authors:  Suresh J Antony; Peter Jurczyk; Lisa Brumble
Journal:  J Natl Med Assoc       Date:  2006-06       Impact factor: 1.798

5.  Comparative efficacies of terbinafine and fluconazole in treatment of experimental coccidioidal meningitis in a rabbit model.

Authors:  K N Sorensen; R A Sobel; K V Clemons; L Calderon; K J Howell; P R Irani; D Pappagianis; P L Williams; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

6.  Efficacy of intravenous liposomal amphotericin B (AmBisome) against coccidioidal meningitis in rabbits.

Authors:  Karl V Clemons; Raymond A Sobel; Paul L Williams; Demosthenes Pappagianis; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

7.  Central nervous system paracoccidioidomycosis in an AIDS patient: case report.

Authors:  Mario León Silva-Vergara; Ivonete Helena Rocha; Rakel Rocha Vasconcelos; André Luiz Maltos; Fernando de Freitas Neves; Luciana de Almeida Silva Teixeira; Delio José Mora
Journal:  Mycopathologia       Date:  2014-01-24       Impact factor: 2.574

8.  Comparative efficacies of lipid-complexed amphotericin B and liposomal amphotericin B against coccidioidal meningitis in rabbits.

Authors:  Karl V Clemons; Javier Capilla; Raymond A Sobel; Marife Martinez; Ann-Jay Tong; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2009-03-09       Impact factor: 5.191

9.  CYP51 is an essential drug target for the treatment of primary amoebic meningoencephalitis (PAM).

Authors:  Anjan Debnath; Claudia M Calvet; Gareth Jennings; Wenxu Zhou; Alexander Aksenov; Madeline R Luth; Ruben Abagyan; W David Nes; James H McKerrow; Larissa M Podust
Journal:  PLoS Negl Trop Dis       Date:  2017-12-28

Review 10.  The Rise of Coccidioides: Forces Against the Dust Devil Unleashed.

Authors:  Marley C Caballero Van Dyke; George R Thompson; John N Galgiani; Bridget M Barker
Journal:  Front Immunol       Date:  2019-09-11       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.